scholarly journals Posterior reversible encephalopathy syndrome as a neuropsychiatric manifestation of systemic lupus erythematosus

2019 ◽  
Vol 25 (5) ◽  
Author(s):  
CM Ho ◽  
CC Mok
2020 ◽  
pp. 102739
Author(s):  
Martín Valdez-López ◽  
Eduardo Aguirre-Aguilar ◽  
Sergio Iván Valdés-Ferrer ◽  
Francisco M. Martínez-Carrillo ◽  
Antonio Arauz ◽  
...  

2018 ◽  
Vol 15 (4) ◽  
pp. 27-34
Author(s):  
Anna Mirela Stroie ◽  
Mircea Nicolae Penescu

AbstractPosterior reversible encephalopathy syndrome is a rare manifestation of systemic lupus erythematosus, characterized by altered mental status, headache, convulsions, visual field impairment and posterior and reversible alterations on imaging scans(1,2). The clinical picture develops over a few hours, presenting with rapidly progressive neurological symptoms(3). It was first described in 1996. It is more frequent in patients with acute kidney injury or chronic kidney disease, thus in lupus patients with kidney disorders. It is associated with hypertension, other autoimmune diseases beside lupus, immunosuppressive therapies, especially antibody-based immunosuppressive therapy, and organ transplantation. It is clinically reversible within one week and imaging changes resolve within 2-4 weeks. It is treatable and has a good prognosis. We present the case of a young woman of 27 years, diagnosed with systemic lupus erythematosus who developed convulsive seizures, headache, visual impairment, being under immunosuppressive therapy with azathioprine. The kidney biopsy revealed class IV lupus nephritis and partial remission of the nephrotic syndrome. The other manifestations of SLE in this patient were cutaneous, immunological, articular and haematological. The patient had a good short, medium and long-term prognosis at 30 days and also at 6 months.


2011 ◽  
Vol 38 (8) ◽  
pp. 1607-1611 ◽  
Author(s):  
IRLAPATI RAJENDRA VARAPRASAD ◽  
SUMEET AGRAWAL ◽  
VADIVELMURUGAN NAGASUBRAMANI NAGA PRABU ◽  
LIZA RAJASEKHAR ◽  
MEENA ANGAMUTHU KANIKANNAN ◽  
...  

Objective.To study the clinical profile of posterior reversible encephalopathy syndrome (PRES) in patients with systemic lupus erythematosus (SLE) and analyze the risk factors and outcomes associated with it.Methods.We identified patients with SLE and PRES from January 2006 to October 2010. Data were collected on demographic details, lupus characteristics, PRES-related features, laboratory abnormalities, treatment details, and outcomes.Results.We studied 13 patients (all female) ages 14–37 years (median 23 yrs; 4 were aged < 18 yrs with juvenile SLE). Duration of lupus ranged from 1.5 to 36 months (median 6 mo). Six patients had PRES as a part of their initial presentation of lupus. All had active lupus and hypertension; 9 had nephritis. Four patients were on treatment with cyclophosphamide therapy when they developed PRES. Antihypertensives and antiepileptics were the mainstay of treatment along with supportive care. Immunosuppressive therapy was guided by lupus-related major organ manifestations. Two patients had focal neurological deficits; one had persistent hemiparesis at followup. One patient died.Conclusion.PRES occurs in young lupus patients and in the early part of the disease. Focal deficits are not uncommon. It can be the presenting manifestation of lupus. Management is predominantly symptomatic. Immunosuppression is directed by other major organ manifestations. Early diagnosis and appropriate management is productive.


Neurology ◽  
2012 ◽  
Vol 78 (Meeting Abstracts 1) ◽  
pp. P02.201-P02.201
Author(s):  
R. Rodriguez-Balaguer ◽  
M. Del Mar Saniger-Alba ◽  
E. Chiquete ◽  
J. Higuera Calleja ◽  
C. Cantu-Brito

Sign in / Sign up

Export Citation Format

Share Document